GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » ROC (Joel Greenblatt) %

Venus Medtech (Hangzhou) (HKSE:02500) ROC (Joel Greenblatt) % : -73.30% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Venus Medtech (Hangzhou)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -73.30%.

The historical rank and industry rank for Venus Medtech (Hangzhou)'s ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:02500' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -861.16   Med: -166.68   Max: -72.37
Current: -77.68

During the past 7 years, Venus Medtech (Hangzhou)'s highest ROC (Joel Greenblatt) % was -72.37%. The lowest was -861.16%. And the median was -166.68%.

HKSE:02500's ROC (Joel Greenblatt) % is ranked worse than
66.39% of 851 companies
in the Medical Devices & Instruments industry
Industry Median: -1.04 vs HKSE:02500: -77.68

Venus Medtech (Hangzhou)'s 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 36.10% per year.


Venus Medtech (Hangzhou) ROC (Joel Greenblatt) % Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) ROC (Joel Greenblatt) % Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -497.30 -95.79 -93.77 -166.68 -72.37

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -118.61 -88.47 -277.79 -89.43 -73.30

Competitive Comparison of Venus Medtech (Hangzhou)'s ROC (Joel Greenblatt) %

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Medtech (Hangzhou)'s ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s ROC (Joel Greenblatt) % falls into.



Venus Medtech (Hangzhou) ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(439.286 + 128.856 + 5.692) - (303.611 + 0 + 4.314)
=265.909

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(317.86 + 123.534 + 314.369) - (307.271 + 0 + 32.313)
=416.179

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Venus Medtech (Hangzhou) for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-729.484/( ( (542.235 + max(265.909, 0)) + (765.965 + max(416.179, 0)) )/ 2 )
=-729.484/( ( 808.144 + 1182.144 )/ 2 )
=-729.484/995.144
=-73.30 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Medtech (Hangzhou)  (HKSE:02500) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Venus Medtech (Hangzhou) ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Traded in Other Exchanges
Address
No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Executives
Zeng Min Frank 2201 Interest of corporation controlled by you
Zi Zhenjun 2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited 2101 Beneficial owner
Ming Zhi Investments Limited 2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p. 2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p. 2201 Interest of corporation controlled by you
Dcp General Partner, Ltd 2201 Interest of corporation controlled by you
Dcp, Ltd. 2201 Interest of corporation controlled by you
Liu Haifeng David 2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited 2101 Beneficial owner
Red Giant Limited 2201 Interest of corporation controlled by you
Wolhardt Julian Juul 2201 Interest of corporation controlled by you
Horizon Binjiang Llc 2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines